Lanhua Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lanhua Tang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Shushan Zhao
Xiangya Hosptial, Central South University
2 shared publications - Xue-Gong Fan
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Li-Zhang Chen
School of Public Health, Central South University, Changsha, Hunan, PR China
1 shared publication Lizhang Chen
Central South University; School of Public Health; 87 Xiang-ya Road Changsha Hunan China 410078
1 shared publication- Lizhang Chen
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Rong-Rong Zhou
Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South University, Changsha, China
1 shared publication
Latest Publications
- Open Access
- 9 March 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 111
Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B.
- 9 March 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 111
Open AccessComparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B.
- 8 September 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 9
Telbivudine for chronic hepatitis B
- 8 September 2010
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 9
Telbivudine for chronic hepatitis B
- Open Access
- 3 September 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 211
Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.
- 3 September 2010
- Published by Springer Nature in Virology Journal
- Vol. 7 (1) , 211
Open AccessComparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.